Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days Read more about Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results Read more about Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer Read more about Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference Read more about Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results Read more about Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day Read more about Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 Read more about Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research Read more about Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares Read more about Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares Larimar Therapeutics Announces $70 Million Underwritten Offering Read more about Larimar Therapeutics Announces $70 Million Underwritten Offering Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days Read more about Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results Read more about Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer Read more about Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference Read more about Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results Read more about Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day Read more about Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 Read more about Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research Read more about Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares Read more about Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
Larimar Therapeutics Announces $70 Million Underwritten Offering Read more about Larimar Therapeutics Announces $70 Million Underwritten Offering